| Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering |
2021-03-24 |
| Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon |
2021-03-24 |
| AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications |
2021-03-10 |
| Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen |
2021-03-08 |
| Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact |
2021-03-03 |
| Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital |
2021-03-03 |
| Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx |
2021-01-21 |
| AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones |
2021-01-20 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag |
2021-01-11 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners |
2020-11-30 |
| Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
| Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
| Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio |
2020-11-23 |
| MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets |
2020-11-11 |
| Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern |
2020-11-10 |
| Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion |
2020-11-10 |
| Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund |
2020-11-10 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group |
2020-10-20 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS |
2020-09-22 |
| Helmholtz–Bruker: NMR spectrometer, 202009c supply 1.2 GHz NMR spectrometer with 28 Tesla to FZ Jülich |
2020-09-01 |
| Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system |
2020-08-24 |
| Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF |
2020-08-11 |
| Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV |
2020-08-11 |
| Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED |
2020-08-02 |
| Quantro Therapeutics–MC Services: public relations, 202007 service existent by MC Services |
2020-07-21 |
| Tubulis–Bavaria (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Bayern Kapital |
2020-07-21 |
| Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners |
2020-07-21 |
| Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners |
2020-07-21 |
| Tubulis–Germany (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Coparion |
2020-07-21 |
| Tubulis–High-Tech Gründerfonds: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor HTGF |
2020-07-21 |
| Tubulis–Occident Group: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group |
2020-07-21 |
| Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF |
2020-07-21 |
| Tubulis–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-21 |
| CureVac–Germany (govt): investment, 202007 financing round Series B totalling €560m incl €300m from KfW approx 19% shareholding |
2020-07-17 |
| CureVac–GSK: investment, 202007 financing round Series B totalling €560m incl €150m from Glaxo Group Ltd |
2020-07-17 |
| CureVac–Qatar (govt): investment, 202007 financing round Series B totalling €560m incl €60m from Qatar Investment Authority |
2020-07-17 |
| CureVac–SEVERAL: investment, 202007 financing round Series B €560m incl €300m from KfW + €150m from GSK + €60m from QIA |
2020-07-17 |
| TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group |
2020-07-16 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Roche–Inveox: sample management software, 202007– collab digitization Vantage Workflow Solution for histopathology labs with Roche Diagnostics |
2020-07-01 |
| Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m led by Optum Ventures + Idinvest + capital300 |
2020-06-18 |
| AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital |
2020-06-02 |
| AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner |
2020-06-02 |
| AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank |
2020-06-02 |
| AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG |
2020-06-02 |
| AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident |
2020-06-02 |
| AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG |
2020-06-02 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
| Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF |
2020-05-27 |
| Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE |
2020-05-27 |
| Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures |
2020-05-27 |
| Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures |
2020-05-27 |
| Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs |
2020-05-26 |
| Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. |
2020-05-26 |
| Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures |
2020-05-26 |
| Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins |
2020-05-19 |
| Rentschler–MC Services: public relations, 202005 service existent by MC Services |
2020-05-19 |
| Oribiotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori |
2020-05-13 |
| Bluebird Bio–Showa Denko: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies |
2020-05-11 |
| Compass Pathways–Atai Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor Atai Life Sciences |
2020-04-27 |
| Heidelberg Pharma–Hopp Group: investment, 202004 private placement totalling €14.4m incl €13.7m from main investor Dievini Hopp |
2020-04-27 |
| Heidelberg Pharma–OTHER: investment, 202004 private placement totalling €14.4m incl €719k to institutional investors |
2020-04-27 |
| Heidelberg Pharma–SEVERAL: investment, 202004 private placement €14.4m with 2.82m new shares at €5.1/share incl €13.7m from Dievini Hopp |
2020-04-27 |
| Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment |
2020-04-16 |
| Leon-Nanodrugs–Albany Private Equity: investment, 202004 financing round Series B incl existing + co-investor Albany Private Equity Holidngs Pty Ltd |
2020-04-16 |
| Leon-Nanodrugs–Bavaria (govt): investment, 202004 financing round Series B incl new + co-investor BayBG |
2020-04-16 |
| Leon-Nanodrugs–CD-Venture: investment, 202004 financing round Series B incl existing + co-investor CD-Venture GmbH |
2020-04-16 |
| Leon-Nanodrugs–Eckenstein-Geigy-Stiftung: investment, 202004 financing round Series B incl existing + co-investor Eckenstein-Geigy-Stiftung |
2020-04-16 |
| Leon-Nanodrugs–Evotec: investment, 202004 financing round Series B incl new + lead investor Evotec |
2020-04-16 |
| Leon-Nanodrugs–LOF Leon Partnership: investment, 202004 financing round Series B incl existing + co-investor LOF Leon Partnership LP |
2020-04-16 |
| Leon-Nanodrugs–SEVERAL: investment, 202004 financing round Series B led by new investor Evotec |
2020-04-16 |
| Leon-Nanodrugs–TVM: investment, 202004 financing round Series B incl existing + co-investor TVM Life Science Innovation I LP |
2020-04-16 |
| Provirex–Helmholtz: investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg |
2020-03-31 |
| DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications |
2020-03-18 |
| Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya |
2020-03-17 |
| iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital |
2020-03-09 |
| iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF |
2020-03-09 |
| iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels |
2020-03-09 |
| iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels |
2020-03-09 |
| GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties |
2020-02-20 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
